|
Name |
2-Methyl-3-benzylidene-6,7,8,8a-tetrahydropyrrolo[1,2-a]pyrazine-1,4(2H,3H)-dione
|
| Molecular Formula | C15H16N2O2 | |
| IUPAC Name* |
(3Z)-3-benzylidene-2-methyl-6,7,8,8a-tetrahydropyrrolo[1,2-a]pyrazine-1,4-dione
|
|
| SMILES |
CN1/C(=C\C2=CC=CC=C2)/C(=O)N3CCCC3C1=O
|
|
| InChI |
InChI=1S/C15H16N2O2/c1-16-13(10-11-6-3-2-4-7-11)15(19)17-9-5-8-12(17)14(16)18/h2-4,6-7,10,12H,5,8-9H2,1H3/b13-10-
|
|
| InChIKey |
SNYXWODAEROITA-RAXLEYEMSA-N
|
|
| Synonyms |
CHEMBL4872269; 3-benzylidene-2-methylhexahydropyrrolo [1,2-a] pyrazine-1,4-dione; 2-Methyl-3-benzylidene-6,7,8,8a-tetrahydropyrrolo[1,2-a]pyrazine-1,4(2H,3H)-dione
|
|
| CAS | NA | |
| PubChem CID | 101115021 | |
| ChEMBL ID | CHEMBL4872269 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 256.3 | ALogp: | 1.7 |
| HBD: | 0 | HBA: | 2 |
| Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 40.6 | Aromatic Rings: | 3 |
| Heavy Atoms: | 19 | QED Weighted: | 0.721 |
| Caco-2 Permeability: | -4.61 | MDCK Permeability: | 0.00003300 |
| Pgp-inhibitor: | 0.016 | Pgp-substrate: | 0.001 |
| Human Intestinal Absorption (HIA): | 0.06 | 20% Bioavailability (F20%): | 0.011 |
| 30% Bioavailability (F30%): | 0.124 |
| Blood-Brain-Barrier Penetration (BBB): | 0.979 | Plasma Protein Binding (PPB): | 71.89% |
| Volume Distribution (VD): | 0.514 | Fu: | 18.50% |
| CYP1A2-inhibitor: | 0.426 | CYP1A2-substrate: | 0.696 |
| CYP2C19-inhibitor: | 0.393 | CYP2C19-substrate: | 0.837 |
| CYP2C9-inhibitor: | 0.186 | CYP2C9-substrate: | 0.207 |
| CYP2D6-inhibitor: | 0.015 | CYP2D6-substrate: | 0.211 |
| CYP3A4-inhibitor: | 0.087 | CYP3A4-substrate: | 0.531 |
| Clearance (CL): | 3.801 | Half-life (T1/2): | 0.441 |
| hERG Blockers: | 0.018 | Human Hepatotoxicity (H-HT): | 0.867 |
| Drug-inuced Liver Injury (DILI): | 0.739 | AMES Toxicity: | 0.021 |
| Rat Oral Acute Toxicity: | 0.265 | Maximum Recommended Daily Dose: | 0.034 |
| Skin Sensitization: | 0.296 | Carcinogencity: | 0.653 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.018 |
| Respiratory Toxicity: | 0.027 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC005322 | ![]() |
0.515 | D06BYV | ![]() |
0.409 | ||
| ENC005971 | ![]() |
0.472 | D08EOD | ![]() |
0.357 | ||
| ENC001087 | ![]() |
0.472 | D05EPM | ![]() |
0.333 | ||
| ENC005484 | ![]() |
0.472 | D04ACW | ![]() |
0.333 | ||
| ENC000825 | ![]() |
0.472 | D07RGW | ![]() |
0.324 | ||
| ENC002980 | ![]() |
0.452 | D08UMH | ![]() |
0.321 | ||
| ENC004695 | ![]() |
0.452 | D0L1WV | ![]() |
0.321 | ||
| ENC004694 | ![]() |
0.452 | D03KOZ | ![]() |
0.318 | ||
| ENC004892 | ![]() |
0.425 | D0R6RO | ![]() |
0.314 | ||
| ENC005321 | ![]() |
0.408 | D05ZIK | ![]() |
0.314 | ||